Collaboration enables the development of Aethlon's Hemopurifier in tandem with SeaStar's cartridges for multiple clinical targets
SAN DIEGO and CARDIFF, Calif., July 1, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD) and SeaStar Medical, Inc. today announced a cross-licensing agreement to jointly develop their respective medical devices to address the care and management of critically ill patients.
Aethlon Medical is developing the Hemopurifier®, a first-in-class blood purification cartridge used to remove a range of different particles from the blood, including cancer promoting exosomes for the treatment of cancers with no adequate alternative therapy and viruses for the treatment of life-threatening viral diseases. SeaStar's platform of cartridges include the CLR 2.0 Hemofilter which is FDA 510K cleared for acute kidney injury (AKI), congestive heart failure (CHF) and pulmonary edema and is currently being marketed for organ preservation in the solid organ transplant market. Each company's cartridges are designed to fit onto standard, hospital ICU-based equipment, either independently or together, and the companies plan to jointly develop complete treatment solutions that will allow deployment into multiple inpatient and outpatient treatment settings in any clinical indication where combined use of the Hemopurifier and CPCs may improve or expand indications for use, including but not limited to infectious disease, oncology and organ preservation and transplant.
"The potential synergy of our two companies' platforms should allow penetration into multiple unaddressed markets," said Timothy C. Rodell, M.D., Interim Chief Executive Officer of Aethlon Medical. "Many solid organ transplant patients' outcomes are impacted by viral infections, including hepatitis C and cytomegalovirus (CMV), so the demonstrated ability of the Aethlon Hemopurifier to clear viruses could be complementary to SeaStar's CLR 2.0's ability to improve donor organ function. Likewise, inflammation has a role in cancer, which could make the SeaStar products complementary to the Hemopurifier."
"Aethlon and SeaStar align on combining their complementary novel medical devices to address critical unmet needs," said Charles J. Fisher Jr., M.D., Chief Executive Officer of SeaStar Medical. "Combinations of the Hemopurifier and the SeaStar cartridges present unique and promising development paths. After joining Aethlon's board of directors in November 2017, I realized that both teams are equally passionate about providing innovative medical products designed to improve the survival of patients with cancer, infectious and inflammatory disorders."
About SeaStar Medical, Inc.
SeaStar Medical's transformative immune and inflammation modulating technology addresses transplantation, inflammation and oncology. This innovative bedside technology has been shown to be safe in humans and has demonstrated a reduction of inflammation and associated tissue injury in organs. SeaStar's name is inspired by the sea star, which possesses both unique anti-inflammatory and anti-cancer properties. For more information, visit http://www.seastarmed.com/.
About Aethlon Medical, Inc.
Aethlon Medical is focused on addressing unmet needs in global health. The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Company believes that the Hemopurifier® depletes the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis, and inhibit the benefit of leading cancer therapies. The Hemopurifier® is an FDA designated "Breakthrough Device" related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies.
Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.
Chief Financial Officer
Aethlon Medical, Inc.
Russo Partners, LLC
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "should", "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to develop and commercialize the Hemopurifier, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Hemopurifier, the Company's ability to raise capital when needed, the risk that the collaboration between the Company and SeaStar will not be successful and even if successful, the products from the effort may not achieve the expected market penetration, the Company's ability to complete the development of its planned products, including any diagnostic products related to the detection of CTE, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in the forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.